[
    [
        {
            "time": "2018-01-02",
            "original_text": "Abbott Gains FDA Nod For A New Diabetes Device, But Dexcom Rockets",
            "features": {
                "keywords": [
                    "FDA",
                    "Nod",
                    "Diabetes",
                    "Device",
                    "Dexcom"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Abbott Gains FDA Nod For A New Diabetes Device, But Dexcom Rockets",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "Abbott Gains New Clearance As Devices Rivalry With Dexcom Builds",
            "features": {
                "keywords": [
                    "Abbott",
                    "Clearance",
                    "Devices",
                    "Rivalry",
                    "Dexcom"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Abbott Gains New Clearance As Devices Rivalry With Dexcom Builds",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Is Abbott Stock A Buy As Worries Of A Second Coronavirus Wave Spread?",
            "features": {
                "keywords": [
                    "Abbott",
                    "Stock",
                    "Buy",
                    "Coronavirus",
                    "Wave"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Is Abbott Stock A Buy As Worries Of A Second Coronavirus Wave Spread?",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "FDA clears new version of Abbott's diabetes glucose monitor",
            "features": {
                "keywords": [
                    "FDA",
                    "clears",
                    "version",
                    "Abbott",
                    "diabetes",
                    "glucose",
                    "monitor"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "FDA clears new version of Abbott's diabetes glucose monitor",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "Abbott's (ABT) FreeStyle Libre Study Outcome Favorable",
            "features": {
                "keywords": [
                    "Abbott",
                    "FreeStyle",
                    "Libre",
                    "Study",
                    "Outcome",
                    "Favorable"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Abbott's (ABT) FreeStyle Libre Study Outcome Favorable",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "Abbott's Bluetooth-Enabled Glucose Monitor Finally Clears FDA Hurdle",
            "features": {
                "keywords": [
                    "Bluetooth-Enabled",
                    "Glucose",
                    "Monitor",
                    "FDA",
                    "Hurdle"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Abbott's Bluetooth-Enabled Glucose Monitor Finally Clears FDA Hurdle",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "U.S. FDA clears new version of Abbott's low-cost glucose monitor",
            "features": {
                "keywords": [
                    "U.S.",
                    "FDA",
                    "clears",
                    "version",
                    "Abbott",
                    "low-cost",
                    "glucose",
                    "monitor"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "U.S. FDA clears new version of Abbott's low-cost glucose monitor",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "U.S. FDA clears version 2.0 of Abbott's low-cost glucose monitor",
            "features": {
                "keywords": [
                    "U.S.",
                    "FDA",
                    "clears",
                    "version",
                    "2.0",
                    "Abbott",
                    "low-cost",
                    "glucose",
                    "monitor"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "U.S. FDA clears version 2.0 of Abbott's low-cost glucose monitor",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-10",
            "original_text": "Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards",
            "features": {
                "keywords": [
                    "Abbott",
                    "FreeStyle®",
                    "Libre",
                    "2",
                    "iCGM",
                    "Cleared",
                    "U.S.",
                    "Adults",
                    "Children",
                    "Diabetes",
                    "Accuracy",
                    "Performance",
                    "Standards"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        }
    ]
]